Wedbush reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report released on Monday, AnalystRatings.com reports. The firm currently has a $35.00 price target on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on LXRX. ValuEngine downgraded shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a report on Monday, May 20th. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a hold rating to a buy rating and set a $6.50 price target for the company in a report on Tuesday, May 28th. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a report on Monday, May 20th. Needham & Company LLC restated a hold rating on shares of Lexicon Pharmaceuticals in a report on Thursday, May 2nd. Finally, Gabelli upgraded shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a report on Monday, March 25th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $16.38.

LXRX stock opened at $5.35 on Monday. The stock has a market capitalization of $568.56 million, a price-to-earnings ratio of -4.69 and a beta of 0.77. Lexicon Pharmaceuticals has a 12 month low of $4.25 and a 12 month high of $13.97.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.21). The business had revenue of $9.20 million during the quarter, compared to the consensus estimate of $13.26 million. Lexicon Pharmaceuticals had a negative net margin of 214.93% and a negative return on equity of 911.37%. The business’s revenue was down 63.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.40) EPS. Equities research analysts expect that Lexicon Pharmaceuticals will post -0.47 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in LXRX. Vanguard Group Inc. boosted its position in shares of Lexicon Pharmaceuticals by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 3,834,766 shares of the biopharmaceutical company’s stock worth $40,917,000 after purchasing an additional 72,640 shares during the period. First Manhattan Co. purchased a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $15,282,000. Clearbridge Investments LLC boosted its position in shares of Lexicon Pharmaceuticals by 3.4% during the 1st quarter. Clearbridge Investments LLC now owns 1,292,130 shares of the biopharmaceutical company’s stock worth $7,184,000 after purchasing an additional 42,540 shares during the period. Pictet Asset Management Ltd. boosted its position in shares of Lexicon Pharmaceuticals by 42.6% during the 1st quarter. Pictet Asset Management Ltd. now owns 586,850 shares of the biopharmaceutical company’s stock worth $3,263,000 after purchasing an additional 175,400 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Lexicon Pharmaceuticals by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 565,085 shares of the biopharmaceutical company’s stock worth $3,752,000 after purchasing an additional 13,664 shares during the period. Institutional investors and hedge funds own 98.30% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Story: Momentum Indicators

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.